Bank of New York Mellon Corp Invests $62.79 Million in Halozyme Therapeutics, Inc. $HALO

Key Points

• Bank of New York Mellon acquired 802,245 Halozyme shares worth approximately $62.8 million, giving it a 0.68% stake. Institutional investors collectively own 97.79% of the company.
• Halozyme exceeded quarterly expectations, reporting $2.28 EPS versus $1.79 expected and $481 million in revenue, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analysts maintain a generally positive outlook, with nine Buy ratings and an overall “Moderate Buy” consensus, although the average price target of $91.20 is below the stock’s reported $107.06 price. Insiders sold 64,103 shares worth $5.23 million over the past 90 days.

Bank of New York Mellon Corp acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 802,245 shares of the biopharmaceutical company's stock, valued at approximately $62,792,000. Bank of New York Mellon Corp owned approximately 0.68% of Halozyme Therapeutics as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC lifted its position in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 343 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 372 shares in the last quarter. Clearstead Advisors LLC increased its position in shares of Halozyme Therapeutics by 64.8% in the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $70,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock valued at $5,226,496 in the last ninety days. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $107.06 on Thursday. The firm has a 50-day moving average price of $85.50 and a two-hundred day moving average price of $74.39. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.66. The company has a market capitalization of $12.15 billion, a P/E ratio of 31.96, a P/E/G ratio of 0.44 and a beta of 0.85. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of analyst reports. Citigroup reiterated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. UBS Group restated a "buy" rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research report on Tuesday, May 12th. Finally, HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source